Ricardo Soto‐Rifo

ORCID: 0000-0003-0945-2970
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • RNA Research and Splicing
  • RNA modifications and cancer
  • HIV Research and Treatment
  • Vaccine Coverage and Hesitancy
  • SARS-CoV-2 detection and testing
  • RNA regulation and disease
  • RNA and protein synthesis mechanisms
  • Viral Infections and Immunology Research
  • RNA Interference and Gene Delivery
  • Respiratory viral infections research
  • Viral gastroenteritis research and epidemiology
  • COVID-19 and Mental Health
  • interferon and immune responses
  • Mosquito-borne diseases and control
  • Bacteriophages and microbial interactions
  • Biosensors and Analytical Detection
  • Animal Virus Infections Studies
  • Study of Mite Species
  • Influenza Virus Research Studies
  • COVID-19 diagnosis using AI
  • Epigenetics and DNA Methylation
  • Cytomegalovirus and herpesvirus research
  • Cancer-related gene regulation

University of Chile
2015-2024

Millennium Institute on Immunology and Immunotherapy
2021-2024

Weatherford College
2020-2021

Institut Pasteur
2021

Instituto Pasteur
2021

Universidad de Magallanes
2021

Instituto de Neurociencia Biomédica
2019

École Normale Supérieure de Lyon
2007-2016

Centre International de Recherche en Infectiologie
2013-2016

Université Claude Bernard Lyon 1
2011-2016

The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports results obtained for healthy Chilean adults aged ≥18 years in phase 3 clinical trial.Volunteers randomly received doses or placebo, separated by weeks. A total 434 volunteers were enrolled, 397 18-59 37 ≥60 years. Solicited unsolicited adverse...

10.1093/cid/ciab823 article EN Clinical Infectious Diseases 2021-09-15

Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP in COVID-19 progression.The study was an open-label, single-center randomized clinical trial performed academic medical center Santiago, Chile, from May 10, 2020, July 18, final follow-up until August 17, 2020. The included within first 7 days symptom onset, presenting risk factors...

10.1371/journal.pmed.1003415 article EN cc-by PLoS Medicine 2021-03-03

ABSTRACT Background The newly described SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO (Lambda variant) based on its high circulation rates in South American countries and presence critical mutations spike protein. impact such infectivity immune escape from neutralizing antibodies are entirely unknown. Methods We performed pseudotyped virus neutralization assay determined Lambda using plasma samples healthcare workers (HCW) two centers Santiago, Chile who...

10.1101/2021.06.28.21259673 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-07-01

Screening, testing and contact tracing plays a pivotal role in control of the COVID-19 pandemic. To enable this it is necessary to increase capacity. This study compared SARS-CoV-2 rapid antigen test (RAT) RT-PCR 842 asymptomatic individuals from Tarapacá, Chile. A sensitivity 69.86%, specificity 99.61%, PPV 94.44% NPP 97.22% with Ct values (Ct > 27) that were significantly higher among false-negative RAT reported. These results support fact might have significant impact on identification...

10.1016/j.ijid.2021.04.087 article EN cc-by-nc-nd International Journal of Infectious Diseases 2021-05-01

CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 4 weeks after two doses CoronaVac; these were significantly reduced at 6 to 8 months doses. Here, we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOCs), Delta Omicron, in adults participating phase III clinical trial Chile. Volunteers immunized with...

10.1128/mbio.01423-22 article EN cc-by mBio 2022-08-10

Here, we show a novel molecular mechanism promoted by the DEAD-box RNA helicase DDX3 for translation of HIV-1 genomic RNA. This occurs through adenosine triphosphate-dependent formation initiation complex that is assembled at 5′ m7GTP cap mRNA. due to property substitute factor eIF4E in binding structure where it nucleates core DDX3/PABP/eIF4G trimeric on By using fluorescence situ hybridization coupled indirect immunofluorescence, further this viral ribonucleoprotein addressed...

10.1093/nar/gkt306 article EN cc-by-nc Nucleic Acids Research 2013-04-27

The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...

10.1101/2021.03.31.21254494 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2021-04-01

During retroviral replication, the full-length RNA serves both as mRNA and genomic RNA. However, mechanisms by which HIV-1 Gag protein selects two molecules that will be packaged into nascent virions remain poorly understood. Here, we demonstrate deposition of N6-methyladenosine (m6A) regulates packaging. While m6A METTL3/METTL14 onto was associated with increased synthesis reduced packaging, FTO-mediated demethylation promoted incorporation viral particles. Interestingly, associates...

10.1093/nar/gkac062 article EN cc-by-nc Nucleic Acids Research 2022-01-26

The COVID-19 pandemic has led to the search for new molecules with antiviral activity against SARS-CoV-2. entry of virus into cell is one main targets inhibiting SARS-CoV-2 infection. Natural products are an important source therapeutic alternatives diseases. Pseudotyped viruses allow study viral inhibitors, and due their simplicity, they screening a large number candidates in Biosafety Level 2 facilities. We used pseudotyped HIV-1 D614G spike glycoprotein test its ability infect...

10.3390/molecules27051743 article EN cc-by Molecules 2022-03-07

microRNAs (miRNAs) regulate gene expression at multiple levels by repressing translation, stimulating deadenylation and inducing the premature decay of target messenger RNAs (mRNAs). Although mechanism which miRNAs repress translation has been widely studied, precise step targeted molecular insights such repression are still evasive. Here, we have used our newly designed in vitro system, allows to study miRNA effect on independently deadenylation. By using specific inhibitors various stages...

10.1093/nar/gks1076 article EN cc-by-nc Nucleic Acids Research 2012-11-17

Unspliced, genomic HIV-1 RNA (vRNA) is a component of several ribonucleoprotein complexes (RNP) during the viral replication cycle. In earlier work, we demonstrated that host upframeshift protein 1 (UPF1), key factor in nonsense-mediated mRNA decay (NMD), colocalized and associated to structural Gag egress. this demonstrate new function for UPF1 regulation vRNA nuclear export. OPEN ACCESS Biomolecules 2015, 5 2809 We establish nucleocytoplasmic shuttling required exists two essential RNPs...

10.3390/biom5042808 article EN cc-by Biomolecules 2015-10-20

Abstract The detection of viruses in sewage is a method environmental surveillance, which allows evaluating the circulation different community. This study presents first results surveillance to detect SARS-CoV-2 virus Santiago, Chile. Using ultracentrifugation associated with RT-qPCR, we detected untreated and treated wastewater samples obtained two treatment plants, together process around 85% from city. report Chile indicates that could be sensitive tool useful as predictive marker...

10.1101/2020.07.02.20145177 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2020-07-03

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by mucosa damage associated to uncontrolled response. This immunological impairment leads altered mediators such as IL-33, which shown increase in the of active UC (aUC) patients. MicroRNAs present a distorted feature inflamed colonic and are potential IL-33 regulating candidates UC. Therefore, we studied microRNA mRNA profiles samples patients, evaluating effect (selected silico analysis its expression patients),...

10.3389/fimmu.2019.02449 article EN cc-by Frontiers in Immunology 2019-11-19

Abstract The ongoing COVID-19 pandemic has reached more than 200 countries and territories worldwide. Given the large requirement of SARS-CoV-2 diagnosis considering that RNA extraction kits are in short supply, we investigated whether two commercial RT-qPCR were compatible with direct detection from nasopharyngeal swab samples. We show one tested is fully suggesting omission an step should be considered diagnosis.

10.1101/2020.03.28.013508 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2020-03-30
Coming Soon ...